Total Funding
54
34
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
140200
AGTC is a biotechnology company conducting human clinical trials of AAV-based gene therapies for the treatment of rare diseases.
Acquired by 
Syncona Partners LLP
- Sue Washer: President & CEOPast Role: Abbott, Pharmaceutical Management and Research
Terence Flotte: Founder
About the Company
Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by
broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.
Women Led
